عرض بسيط للتسجيلة

المؤلفKhan, Muhammad Yasir
المؤلفAljehani, Najwa D.
المؤلفAbdulal, Rwaa H.
المؤلفGhazwani, Aishah
المؤلفAlsulaiman, Reem M.
المؤلفEyouni, Mais
المؤلفShebbo, Salima
المؤلفBasabrain, Mohammad
المؤلفSanki, Mohammad A.
المؤلفAlsharef, Asem A.
المؤلفAbdulaal, Wesam H.
المؤلفAlbukhari, Ashwag
المؤلفQadri, Ishtiaq
المؤلفAlluhaybi, Khalid A.
المؤلفAltorki, Tarfa
المؤلفAlhabbab, Rowa
المؤلفAlghanmi, Maimonah
المؤلفZawawi, Ayat
المؤلفAbujamel, Turki S.
المؤلفAlgaissi, Abdullah
المؤلفThulasi Raman, Sathya N.
المؤلفAlfaleh, Mohamed A.
المؤلفAlghamdi, Badrah S.
المؤلفAzhari, Ala A.
المؤلفLi, Xuguang
المؤلفMahmoud, Ahmad Bakur
المؤلفHashem, Anwar M.
تاريخ الإتاحة2025-11-27T09:20:04Z
تاريخ النشر2026-01-01
اسم المنشورVaccine
المعرّفhttp://dx.doi.org/10.1016/j.vaccine.2025.127975
الاقتباسKhan, Muhammad Yasir, Najwa D. Aljehani, Rwaa H. Abdulal, Aishah Ghazwani, Reem M. Alsulaiman, Mais Eyouni, Salima Shebbo et al. "Intranasal CD40-targeted recombinant MERS-CoV S1 protein is superior to intramuscular immunization in eliciting systemic and mucosal immune responses in mice." Vaccine 69 (2026): 127975.
الرقم المعياري الدولي للكتاب0264410X
معرّف المصادر الموحدhttps://www.sciencedirect.com/science/article/pii/S0264410X25012733
معرّف المصادر الموحدhttp://hdl.handle.net/10576/68824
الملخصThe Middle East respiratory syndrome coronavirus (MERS-CoV) is a global One Health challenge with a potential pandemic threat, with no approved vaccines or antiviral drugs available to date. Thus, there is an urgent need for a safe and effective vaccine. Herein, we developed a recombinant subunit self-adjuvanted fusion protein vaccine targeting the MERS-CoV S1 subunit to CD40-expessing APCs (S1-F/CD40L). We found that intramuscular injection of S1-F/CD40L in conjunction with Alum and CpG was superior to Alum or CpG alone in terms of systemic Ag-specific humoral and cellular responses and Th1-dominant phenotype. Furthermore, the immunogenicity of co-adjuvanted S1-F/CD40L was compared to that of S1 alone via both intramuscular and intranasal immunization. Two intramuscular and intranasal doses of S1-F/CD40L and S1 were immunogenic in eliciting systemic and mucosal humoral and cellular immunity, including IgG, IgA, neutralizing antibodies (nAbs), and T cell responses in mice, with a greater response in the CD40-targeted S1 group. Intranasal vaccination with S1-F/CD40L induced systemic humoral and cellular immune responses comparable to those induced by intramuscular vaccination, including binding and nAbs and T cell responses. Importantly, intranasal vaccine was able to elicit significantly higher local mucosal humoral and cellular immune responses in mouse lungs and markedly elevated circulating IgA levels compared to intramuscular vaccination. Collectively, our results suggest that the S1-F/CD40L vaccine co-adjuvanted with Alum and CpG can be used as an effective and safe mucosal candidate vaccine against MERS-CoV. Furthermore, these data demonstrate that the incorporation of CD40L as APCs targeting ligand and molecular adjuvant enhances immunogenicity, thus offering a promising platform that could be explored further to respond to future emerging pathogens and possible outbreaks.
راعي المشروعThis work was funded by Community Jameel - Saudi Arabia under Jameel Fund for Infectious Disease Research and Innovation under grant no. JML: 004-141-2024. The authors would also like to thank the Deanship of Scientific Research (DSR) at King Abdulaziz University, Jeddah, Saudi Arabia for their support.
اللغةen
الناشرElsevier
الموضوعMERS-CoV
Intranasal
Intramuscular
CD40L
Adjuvants
Antigen-presenting cells
العنوانIntranasal CD40-targeted recombinant MERS-CoV S1 protein is superior to intramuscular immunization in eliciting systemic and mucosal immune responses in mice
النوعArticle
رقم المجلد69
Open Access user License http://creativecommons.org/licenses/by/4.0/
ESSN1873-2518
dc.accessType Full Text


الملفات في هذه التسجيلة

Thumbnail

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة